Gates Package — page 252

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Merck & Co., Inc. Sylva Collins, Ph.D. Director, Office of Biostatistics U.S. Food and Drug Administration Judith Currier, M.D. Professor of Medicine, University of California, Los Angeles; Chair, AIDS Clinical Trial Group Angelo DeClaro, M.D. Division Director (Acting), Division of Hematologic Malignancies, Center for Drug Evaluation and Research U.S. Food and Drug Administration Ruxandra Draghia-Akli, M.D., Ph.D. Global Head, Global Public Health R&D Janssen Pharmaceutical Companies of Johnson & Johnson Mark Eisner, M.D., M.P.H. Senior Vice President, Global Head of Immunology, Infectious Disease, and Ophthalmology Clinical Development Genentech John Farley, M.D., M.P.H. Director, Office of Infectious Diseases, Center for Drug Evaluation and Research U.S. Food and Drug Administration Carl Garner, M.S., Ph.D. Vice President, Global Regulatory Affairs Eli Lilly and Company David Goff, M.D., Ph.D. Director, Division of Cardiovascular Sciences National Heart, Lung, and Blood Institute, NIH Keith Gottesdiener, M.D. Retired; past President and Chief Executive Officer Rhythm Pharmaceuticals Elizabeth Higgs, M.D., M.1.A., DIM&H Global Health Science Advisor for the Division of Clinical Research National Institute of Allergy and Infectious Diseases, NIH Eric Hughes, M.D., Ph.D. (Co-Chair) Global Development Unit Head, Immunology, Hepatology & Dermatology and China Region Development Head Novartis